---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-003003"
form_type: "8-K/A"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2024-02-05T23:59:59+00:00"
generated_at: "2026-06-06T09:03:19.153233+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zevra completes Acer acquisition; pro forma net loss $59.5M for 9-mo 2023

## Summary
- Pro forma net loss of $59.5M for nine months ended Sep 30, 2023; $80.7M for FY 2022.
- Acer acquisition closed Nov 17, 2023; exchange ratio 0.1210 Zevra shares per Acer share plus CVR.
- Pro forma shares outstanding ~37.8M; Zevra issued ~2.96M shares for Acer equity.
- Zevra purchased Acer's SWK term loans ($18.2M) and Marathon convertible notes ($12.0M).
- Bridge loan of $10M provided to Acer; $1.5M anniversary payment due to Relief Therapeutics.

## SEC filing metadata
- accession: 0001437749-24-003003
- form_type: 8-K/A
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2024-02-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774924003003/0001437749-24-003003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774924003003/zvra20240126_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-003003
- JSON: https://secwatch.observer/filing/0001437749-24-003003.json
- Plain text: https://secwatch.observer/filing/0001437749-24-003003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.